Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is the third most common cancer diagnosed in the United States, with more than 53,000 new cases in 2017. It is the fourth leading cause of cancer-related death in both men and women. Nonetheless, there has been no significant improvement in survival for pancreatic ductal adenocarcinoma (PDAC) patients over the past 30+ years. For this reason, there is a considerable and urgent clinical need to develop innovative strategies for effective drug delivery and treatment monitoring, resulting in improved outcomes for patients with PDAC.
This chapter describes the development of contrast-enhanced ultrasound image-guided drug delivery (CEUS-IGDD or sonoporation) to be that method and to translate it from the lab to the clinic. The initial clinical focus has been on a Phase I clinical trial for enhancing the effectiveness of standard chemotherapeutics for treatment of inoperable PDAC, which demonstrated a median survival increase from 8.9 months to 17.6 months in ten subjects augmented with sonoporation compared to 63 historical controls (p = 0.011). Recent efforts to optimize this platform and move forward to a larger Phase II clinical trial will be described.
Key wordsPancreatic ductal adenocarcinoma Contrast-enhanced ultrasound imaging Sonoporation Augmented chemotherapy delivery Human clinical trial
- 21.Castle J, Feinstein SB (2014) Ultrasound-directed, site specific gene delivery. In: Jain KK (ed) Drug delivery system, 2nd edn. Springer, New York, NYGoogle Scholar
- 28.Phenix CP, Togtema M, Pichardo S, Zehbe I, Curiel L (2014) High intensity focused ultrasound technology, its scope and applications in therapy and drug delivery. J Pharm Sci 17(1):136–153Google Scholar
- 29.Goldberg B, Raichlen J, Forsberg F (2001) Ultrasound contrast agents: basic principles and clinical applications. Taylor & Francis, AbingdonGoogle Scholar
- 47.Eisenbrey J, Merton D, Liu J, Fox T, Sridharan A, Forsberg F (2013) Ultrasound contrast agent-based vascularity measurements versus photoacoustic derived hemoglobin and oxygenation measurements in a breast cancer model (abstract). World Mol Imaging Congr 2013:P563Google Scholar
- 48.Eisenbrey J, Marshall A, Liu J, Sridharan A, Forsberg F (2013) Comparing photoacoustically derived hemoglobin and oxygenation measurements and ultrasound contrast agent derived vascularity measurements to immunohistochemical staining in a breast cancer xenograft model (abstract). Prog RSNA 2013:CL-MIS-MO1BGoogle Scholar
- 49.Eisenbrey JR, Merton DA, Marshall A et al (2015) Comparison of photoacoustically derived hemoglobin and oxygenation measurements with contrast-enhanced ultrasound estimated vascularity and immunohistochemical staining in a breast cancer model. Ultrason Imaging 37(1):42–52PubMedCrossRefGoogle Scholar